Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations

This is a multicenter, retrospective, observational real-world study designed based on real-world data. Eligible medical institutions that meet standardized data quality requirements and have an adequate sample size will be enrolled in this study. The treatment group consists of patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who received adjuvant icotinib therapy after radical resection. The control group includes patients with completely resected (R0) stage IA2 high-risk to IB NSCLC with positive EGFR-sensitizing mutations who received routine observational follow-up after surgery. Propensity score-matched analyses will be conducted between the treatment and control groups to evaluate the efficacy and safety of adjuvant icotinib therapy in this patient population.

Start Date01 Sep 2026

Sponsor / Collaborator

Betta Pharmaceuticals Co., Ltd.

NCT07458919

/ Not yet recruitingEarly Phase 1IIT

A Comparative Study on the Efficacy of First-generation Versus Third-generation EGFR TKIs as First-line Therapy for Advanced NSCLC With EGFR Exon 19 Deletion-insertion (19delins) Mutation

In a retrospective analysis of 3,054 advanced NSCLC patients, 41 with EGFR exon 19 deletion-insertions (19delins) received first-generation EGFR TKIs, achieving median PFS of 10.4 months; those with L747_T751delinsP had notably longer PFS of 18.7 months. Another study of 2,467 treatment-naïve patients found 93 with 19delins treated with first-generation TKIs had median PFS of 19 months, exceeding the 13 months for common 19del mutations. For third-generation TKIs, a study of 215 19delins patients (57 first-line) showed median PFS of 12.9 months, inferior to 23.2 months for common 19del. Our center's retrospective study of 4,666 NSCLC patients in Fujian (2017-2020) included 69 with 19delins: median PFS was 16.7 months with first-generation TKIs versus 7.2 months with third-generation. Evidence suggests specific EGFR deletion locations may affect TKI efficacy; first-generation TKIs may be superior in some 19delins subtypes, while third-generation appear limited. Large prospective data are lacking. This project aims to compare first- versus third-generation EGFR TKIs in 19delins patients via a randomized controlled trial, stratify sensitivity by subtype, and improve survival.

Start Date30 Mar 2026

Sponsor / Collaborator

900th Hospital of Joint Logistics Support Force of PLA

ChiCTR2500112620

/ SuspendedPhase 4IIT

A randomized controlled clinical study on postoperative adjuvant targeted therapy and MRD observation for stage IA non-small cell lung cancer

Start Date01 Sep 2025

Sponsor / Collaborator

Beijing Chest Hospital

100 Clinical Results associated with Icotinib Hydrochloride

100 Translational Medicine associated with Icotinib Hydrochloride

100 Patents (Medical) associated with Icotinib Hydrochloride

519

Literatures (Medical) associated with Icotinib Hydrochloride

01 Oct 2026·DIAGNOSTIC CYTOPATHOLOGY

Pleural Fluid Cytology Detects Small Cell Carcinoma Transformation in EGFR ‐Mutant Lung Adenocarcinoma: A Case Report

Article

Author: Zheng, Chang ; Liang, Yanli ; Zhao, Sihan ; Liu, Lianghua ; Wang, Zhuo ; He, Zhengyue ; Zhou, Huijun

ABSTRACT:

Background:

Histological transformation of lung adenocarcinoma to small cell carcinoma is a rare but critical mechanism of acquired resistance to EGFR‐TKIs.

Case:

A 65‐year‐old woman with EGFR‐mutant lung adenocarcinoma developed new‐onset massive pleural effusion after an initial partial response to icotinib. Pleural fluid cytology revealed tumor cells with high nuclear‐to‐cytoplasmic ratio, finely granular chromatin, and nuclear molding, features suggestive of small cell carcinoma. Cell block immunohistochemistry confirmed small cell carcinoma (CD56+, Syn+, TTF‐1+). Molecular testing demonstrated persistence of the original EGFR exon 19 deletion mutation, and single‐cell sequencing supported clonal origin.

Conclusion:

Integrated cytological and molecular analysis of pleural fluid can provide compelling evidence supporting small cell transformation in EGFR‐mutant lung adenocarcinoma. The shared EGFR mutation between the primary and transformed tumors is consistent with clonal evolution. This minimally invasive approach offers a practical alternative to tissue re‐biopsy for monitoring acquired resistance to EGFR‐TKIs.

01 Sep 2026·Clinical Lung Cancer

Clinical Efficacy and Safety of Icotinib as Adjuvant Therapy for Resected Stage IA Lung Adenocarcinoma: A Real-world Study

Article

Author: Hu, Yi ; Yang, Han ; Zhang, Xin ; Li, Shi-Ning ; Zhong, Le-Qi ; Luo, Si-Sheng ; Liu, Xinyu ; Ao, Yong

BACKGROUND:

The clinical benefit of adjuvant therapy in patients with stage IA non-small cell lung cancer remains uncertain. This real-world study was conducted to assess the effectiveness and safety of icotinib as postoperative adjuvant therapy in patients with stage IA lung adenocarcinoma.

PATIENTS AND METHODS:

This real-world study enrolled 386 patients with pathologically confirmed stage IA lung adenocarcinoma who underwent curative-intent complete resection (lobectomy or sublobar resection) with lymph node dissection or sampling from June 2014 to July 2024. Among them, 128 patients (33.2%) received icotinib as postoperative adjuvant targeted therapy (TKI group), while 258 patients (66.8%) were managed with clinical observation (CO group). Propensity score matching (1:1) yielded 89 well-balanced pairs. The primary endpoint was disease-free survival (DFS). DFS and overall survival (OS) were estimated using the Kaplan-Meier method.

RESULTS:

The median follow-up for the overall cohort was 35.88 months (range 12.71-131.42). After PSM, 1 patient (1.1%) in the TKI group and 12 patients (13.5%) in the CO group experienced disease relapse. The 3-year DFS rate was 100.0% in the TKI group versus 86.8% in the CO group (hazard ratio [HR] 0.07; 95% confidence interval [CI] 0.01-0.50; P = .008). Multivariable Cox regression analysis further identified adjuvant EGFR-TKI therapy as an independent predictor of improved DFS (HR 0.08; 95% CI 0.01-0.50; P = .007). No patient discontinued EGFR-TKI therapy owing to treatment-related severe adverse events.

CONCLUSION:

Compared with clinical observation, adjuvant icotinib was associated with a significant improvement in DFS among patients with stage IA lung adenocarcinoma and exhibited a favorable safety and tolerability profile.

01 Jul 2026·Thoracic Cancer

Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report

Article

Author: Wang, Dan‐He ; Zhu, Yan ; Wang, Chan ; Hu, Nan‐Lin ; Wu, Shi‐Kai

ABSTRACT:

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR‐mutant non–small‐cell lung cancer (NSCLC) is heterogeneous, and serial re‐biopsy may uncover actionable mechanisms. We report a 55‐year‐old man with stage IVB lung adenocarcinoma harboring EGFR L858R and TP53 R282W. First‐line icotinib produced a partial response (PR) with progression‐free survival (PFS) of 7 months. Rebiopsy at progression identified acquired EGFR T790M together with a MET c.3010C>G exon 14‐related alteration. Almonertinib induced a second PR lasting 7 months. After renewed progression, almonertinib plus savolitinib achieved another PR for 8 months, supporting MET‐dependent bypass resistance. Biopsy of a newly progressive iliac metastasis then showed emergence of RET‐CCDC6 fusion, whereas T790M and the MET alteration were no longer detected. Because selective RET inhibition was initially unaffordable, the patient received pemetrexed‐carboplatin plus continued almonertinib, followed by selpercatinib plus almonertinib. Local radiotherapy to oligoprogressive bone and lung lesions prolonged benefit from systemic therapy. At the latest follow‐up in January 2026, the patient remained alive nearly 50 months after diagnosis. This case illustrates clonal evolution under treatment pressure and highlights three practical lessons: repeat molecular testing at each clinically meaningful progression, matched combination targeted therapy for actionable bypass alterations, and local ablative radiotherapy for oligoprogression.

News (Medical) associated with Icotinib Hydrochloride

19 Dec 2024

·www.fiercepharma.com

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer

Before the FDA go-ahead, ensartinib was first approved in China in 2020. Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new entrant is ensartinib from Xcovery Holdings, a subsidiary of China’s Betta Pharmaceuticals. The FDA on Wednesday approved the drug under the brand name Ensacove as a first-line treatment for ALK-positive non-small cell lung cancer among patients who’ve not previously received an ALK inhibitor.Before the FDA go-ahead, ensartinib was first approved in China in 2020 under the trade name Beimeina. There, the drug moved into the first-line setting in 2022.Betta noted that Ensacove marks the first innovative targeted lung cancer drug developed by a Chinese company to make it to the global market. Still, the drug is entering a niche market dominated by Big Pharma companies.As a second-generation ALK inhibitor, Ensacove is clearly better than Pfizer’s first-generation Xalkori. But Roche’s Alecensa, Takeda’s Alunbrig and Pfizer’s third-generation med Lorbrena have all outperformed Xalkori to secure their respective first-line approvals from the FDA. Novartis also has an ALK inhibitor, Zykadia, which was cleared for first-line treatment in 2017 based on a comparison with chemotherapy.The FDA’s nod for Ensacove came more than three years after results from the drug’s first-line eXalt3 study were published in JAMA Oncology. Compared with Xalkori, Ensacove reduced the risk of progression or death by 44% in first-line ALK-positive NSCLC, according to the FDA. No statistically significant difference in overall survival was observed, as Ensacove was linked to a non-statistically significant 12% lower risk of death.The data cited by the FDA, which will be featured on Ensacove’s U.S. label, appear to come from a longer follow-up of eXalt3. Ensacove’s efficacy data were not very differentiated compared with those Big Pharma offerings that have been available on the U.S. market for years.The current ALK leader, Roche’s Alecensa, broke into the first-line ALK setting seven years ago after the phase 3 ALEX trial showed it slashed the risk of disease worsening or death by 47% versus Xalkori. The number later expanded to 57% at the trial’s final progression-free survival analysis. By that time, overall survival data were also immature but showed a 33% improvement trend in favor of the Roche med.What’s more, Alecensa in April jumped into early-stage disease with a first-in-class FDA nod to treat ALK-positive NSCLC as an adjuvant treatment following tumor resection.Ensacove has its own ongoing phase 3 in the adjuvant setting, albeit only among Chinese patients. It’s estimated that about 5% of NSCLC cases are ALK-positive, and treatment can last for a long time for many patients. In the first nine months of 2024, Alecensa brought in 1.15 billion Swiss francs ($1.28 billion) in sales, while Pfizer’s Lorbrena commanded $538 million and Takeda’s Alunbrig generated 25.6 billion Japanese yen ($163 million). Still, those are large numbers compared with Betta’s 2.34 billion Chinese yuan ($321 million) of total revenue earned during the same period from five products, including ensartinib in China.Betta Pharma is revered as a pioneer in China’s biotech industry. The company’s EGFR tyrosine kinase inhibitor icotinib, a competitor to AstraZeneca’s Tagrisso, was the first targeted cancer drug invented and fully owned by a Chinese company. Its approval by Chinese authorities in 2011 was hailed as a landmark event.But the company has fallen behind many of its peers because of its heavy reliance on traditional small-molecule drugs rather than newer technologies.

Drug ApprovalPhase 3Clinical ResultBiosimilar

29 Nov 2024

·www.echemi.com

Pfizer Partners with China Resources for Operations of Four Oncology Drugs in China!

On November 26, 2024, Pfizer announced a strategic cooperation with China Resources Pharmaceutical Commercial to manage the commercialization of four oncology treatments in China. These medications include Anastrozole, Abiraterone, Palbociclib, and Crizotinib, which will be managed by China Resources. Pfizer’s China President, Peng Zhenke, and China Resources’ Deputy General Manager, Han Yuewei, attended the signing ceremony. Among these drugs, Icotinib and Epirubicin have already been included in the alliance procurement list, while Palbociclib and Crizotinib are subject to national negotiations, resulting in significant price reductions. Palbociclib also appeared in the newly published tenth national procurement list, indicating further price cuts. The collaboration will commence on December 1, with Pfizer working closely with China Resources to ensure a smooth transition for affected employees.

30 May 2023

·www.globenewswire.com

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater China and Eligible to Receive Royalties on Net Sales Outside of Greater China The Exclusive Licensing Agreement with Betta Pharmaceuticals Accelerates Development of CFT8919 in Key International Markets WATERTOWN, Mass. and HANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, and Betta Pharmaceuticals Co. Ltd (Betta) (SZ300558), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China, today announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR and Taiwan). CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients. Under the terms of the agreement, C4T expects to receive $35 million, which includes $10 million in upfront cash as well as a $25 million one-time equity investment, to be completed following the receipt of required regulatory approvals and other customary closing conditions. Additionally, C4T is eligible for up to $357 million in potential milestones and low to mid-double-digit percent royalties on net sales in the licensed territories. Betta will be responsible for the development, manufacturing and commercialization of CFT8919 in the licensed territories and is eligible to receive low single-digit percent royalties on net sales outside of Greater China. C4T retains the right to develop and commercialize CFT8919 in all territories outside of Greater China. “We are excited to partner with Betta to develop CFT8919, an orally bioavailable allosteric EGFR L858R degrader, with the potential to treat NSCLC patients with EGFR L858R mutations in Greater China and beyond,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “With their strong track record of developing and commercializing NSCLC therapies in China, we believe Betta is the ideal partner to advance CFT8919 clinical development in a region where there is a high prevalence of lung cancer patients with the EGFR L858R mutation.” “The collaboration with C4T is another important collaboration for Betta’s partnerships with top-tier biotech companies,” said Lieming Ding, chairman and chief executive officer of Betta. “The collaboration will further expand Betta’s product pipeline and improve the productivity of the company's R&D, from discovery to clinical development, and to commercialization. We will leverage the capabilities and resources of both parties and continue developing innovative drugs to benefit more patients.” In preclinical studies, CFT8919 is active in in vitro and in vivo models of EGFR L858R driven NSCLC with broad coverage of on-target resistant mutations and intracranial activity, with the potential to prevent or treat brain metastases in these patients. CFT8919 has been designed to bind to an allosteric site, which is uniquely created by the L858R activating mutation, allowing for exquisite selectivity for this mutation. Further, CFT8919 was designed to be effective independent of secondary EGFR mutations, for example T790M and/or C797S. Additionally, CFT8919 demonstrated potent anti-proliferation activity against a panel of cell lines harboring either L858R single mutation or L858R with additional EGFR mutations that confer resistance to approved EGFR inhibitors such as osimertinib or erlotinib, while sparing cell lines with wild-type EGFR. In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation. The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China. Typically, these patients experience a less durable response to approved EGFR inhibitors, including osimertinib. C4T is on track to submit an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for CFT8919 for the treatment of NSCLC in the first half of 2023. MSQ Ventures served as an advisor to C4T and Goodwin Procter LLP served as legal counsel to C4T. Han Kun Law Offices served as legal counsel to Betta. About CFT8919CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M, and L858R-T790M-C797S. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com. About Betta PharmaceuticalsBetta Pharmaceuticals Co., Ltd. (SZ300558) is a commercial-staged pharmaceutical company dedicated to the development of innovative oncology products to meet high unmet medical needs. With about 2,000 employees in Hangzhou and Beijing, Betta's integrated R&D platform ranges from small-molecule to biologics discovery, clinical development, manufacturing, sales and marketing. Betta's leading product – icotinib (Conmana®), the first innovative oncology product domestically developed and launched in China – is one of the top selling targeted therapies for patients with non-small cell lung cancer, having achieved more than 13 billion RMB accumulated sales since launched and benefited more than 500,000 patients in China. Betta currently has 3 marketed products, 15 programs in clinical development and 2 molecules under NDA review by the NMPA. Throughout the years, Betta has set up strategic partnerships with Xcovery LLC., Merus N.V., Agenus Inc. and other top-tier biotech companies, with the ultimate objective to deliver innovative health solutions around the world. For more information, please visit http://www.bettapharma.com/en.php. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; regulatory developments in the United States and foreign countries; our ability to fund our future operations; our ability to realize development and commercialization milestones and receive royalties on the commercial sale of our product candidates; our ability to realize the anticipated benefits of this collaboration; and our ability to complete the contemplated sale of equity securities. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. C4T Contacts:Investors: Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com Media: Loraine Spreen Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com Betta Pharmaceuticals Contact:Jianhao Shen Director, Securities AffairsJianhao.shen@bettapharma.com

License out/in

100 Deals associated with Icotinib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D11251	Icotinib Hydrochloride	L01EB08	DB11737

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	China	Betta Pharmaceuticals Co., Ltd.	07 Jun 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer with Brain Metastasis	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	20 Jul 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	02 Jun 2015
Adenocarcinoma of Lung	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR Mutation Lung Cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR positive non-small cell lung cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
Advanced Lung Adenocarcinoma	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
EGFR positive Adenocarcinoma of Lung	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
Brain metastases	Phase 2	-	Betta Pharmaceuticals Co., Ltd.	01 Dec 2018
Non-small cell lung cancer stage IIIB	Phase 2	China	Betta Pharmaceuticals Co., Ltd.	09 May 2018
progressive non-small cell lung cancer	Phase 2	China	Betta Pharmaceuticals Co., Ltd.	01 Jan 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02125240 (ICWIP, Pubmed \| Signal Transduct Target Ther)	Phase 3	EGFR positive Adenocarcinoma of Lung Adjuvant EGFR mutated	135	Icotinib	bbfoiclmuc(ukvpmigsgt) = mzaedlcahk oujnykbrev (jkegkziwvn, 39.9 - 73.1) View more	Positive	28 Aug 2026
				Placebo	bbfoiclmuc(ukvpmigsgt) = tieqefcgcy oujnykbrev (jkegkziwvn, 19.9 - 52.6) View more
ESMO_ELCC2026	Not Applicable	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR-mutated	1,236	Adjuvant icotinib alone	yulxhrjlfx(hlpxidiwgt) = Most common adverse events were rash (43.7%), diarrhea (23.2%) and raised aminotransferases (18.9%). yllmzaicmy (bcjnwhcuus )	Positive	25 Mar 2026
				Adjuvant icotinib with chemotherapy
ChiCTR2100044216 (Pubmed) Manual	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	24	Aumolertinib+Icotinib	kksvotsasr(pswxzlejop) = was 125 mg icotinib three times daily plus 110 mg aumolertinib once daily. sppevdsexf (dyanmdvtvf ) View more	Positive	23 Feb 2026
NCT01996098 (ICTAN \| GASTO1002, Signal Transduct Target Ther \| NEWS 1 \| NEWS 2) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	251	Icotinib 125 mg, three times daily for 12 months	yghwiaoedd(apjvkssvcf) = nzykqupipg qlfpysqgbf (qqeamozyoy ) View more	Positive	28 Aug 2025
				Icotinib 125 mg, three times daily for 6 months	yghwiaoedd(apjvkssvcf) = riwljpumeg qlfpysqgbf (qqeamozyoy ) View more
NCT02264210 (CORIN (GASTO1003), ASCO2025)	Phase 2	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR-mutated	128	Icotinib (125mg, three times daily, 12 months)	kytolnaiio(grldrbaxck) = cvtdxlvjib eazlxvxtld (ppwhihxclf ) View more	Positive	30 May 2025
				icotinib (Observation)	kytolnaiio(grldrbaxck) = dofdvxmzrn eazlxvxtld (ppwhihxclf ) View more
NEWS Manual	Phase 3	EGFR positive non-small cell lung cancer EGFR L858R \| EGFR Exon 19 Deletion	118	埃克替尼单药组	dmeffqbori(ezpidyssvf) = hzmqiftxdi dqsagqsvxz (ayzfoxmmgg ) View more	Positive	14 Oct 2024
				埃克替尼联合TRT组	dmeffqbori(ezpidyssvf) = pkvjxksgiz dqsagqsvxz (ayzfoxmmgg ) View more
EVIDENCE (WCLC2024)	Phase 3	EGFR positive non-small cell lung cancer Adjuvant ctDNA-based molecular residual disease (MRD)	179	Icotinib	piluxqyofo(yiaqmhdogm): HR = 0.4 (95% CI, 0.2 - 0.6)	Positive	10 Sep 2024
				Chemotherapy
ChiCTR1800016948 \| NCT05104788 (NEOIPOWER, WCLC2024) Manual	Phase 2	EGFR positive Adenocarcinoma of Lung Neoadjuvant EGFR Mutation	133	Chemotherapy	qusuysfzwp(lggovecqkw) = zdgxobqfrs qmoszeygor (xkkwgbgspx )	Positive	09 Sep 2024
				First-generation EGFR-TKIs	qusuysfzwp(lggovecqkw) = hduinwncrv qmoszeygor (xkkwgbgspx )
NCT01996098 (ICTAN, GASTO1002, ASCO2024) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	251	Icotinib 12 months	ndljxbpigs(nbibtwlbbp) = silptluaoo fzrsxbnrhv (niuzcjgmbg, 43.3 - 80.3) View more	Positive	24 May 2024
				Icotinib 6 months	ndljxbpigs(nbibtwlbbp) = nixisokrwf fzrsxbnrhv (niuzcjgmbg, 44.8 - 81.6) View more
WCLC2023 Manual	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	24	Aumolertinib+Icotinib	otsbujyozb(sglwwxgbml) = aumolertinib 110 mg po qd plus icotinib 125mg po tid ujhfpulwge (emgdmovbqq ) View more	Positive	11 Sep 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis